Loading...
Market
Which microbiome will the first peptide antibiotic to enter Phase 3 clinical trials be derived from by December 31, 2024?
4
Resolution / Starting Odds
Gut microbiome • 25%
Skin microbiome • 25%
Oral microbiome • 25%
Other • 25%
Clinical trial databases and announcements
Story
New Peptide Antibiotics from Human Microbiomes Offer Hope Against Antimicrobial Resistance
Aug 20, 2024, 11:42 AM
Researchers have discovered hundreds of new antibiotics derived from human microbiomes, as reported by Cell Press. This discovery highlights the potential of human microbiomes as a source of peptide antibiotics, which could be crucial in combating antimicrobial resistance. The study identifies dozens of peptides from the human gut microbiome that may serve as effective antibiotics against drug-resistant bacteria. Experts describe this approach of mining human microbiomes for antimicrobial peptides as a promising path forward.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Successful with expected results • 25%
Partially successful • 25%
Unsuccessful • 25%
Results inconclusive • 25%
Yes, identified and announced • 33%
Yes, identified but not announced • 33%
No, not identified • 33%
Respiratory infections • 25%
Bloodstream infections • 25%
Gastrointestinal infections • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
GSK • 25%
Other • 25%
